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ally use intraprocedural activated clotting time (ACT) of4300–350
seconds to prevent thromboembolic events.
OBJECTIVE To evaluate bleeding and thromboembolic procedural
complications in patients with symptomatic AF undergoing ablation
procedures with low intraprocedural ACT.
METHODS We examined a subset of 372 of 2334 (15.9%) AF ablation
procedures using open-irrigated tip radiofrequency catheters at 50 W,
interrupted oral anticoagulation, and a target ACT of 225 seconds,
with average ACTr210 seconds.
RESULTS There were 372 ablation procedures in 339 patients with
average ACT r210 seconds. Patient demographic characteristics
were as follows: age 60.9 9.4 years, men 269 (79.3%), left atrial
(LA) size 4.27 0.65 cm, prior stroke/transient ischemic attack 24
(7.1%), CHADS2 score 0.94 0.98, and CHA2DS2-VASc score 1.53
1.35. AF type was categorized as paroxysmal in 107 (31.6%),
persistent in 200 (59.0%), and long-standing persistent in 32
(9.4%). Procedural and LA times were 119  26 and 82  24
minutes. Patients underwent preprocedure transesophageal echo-
cardiography. The heparin bolus (8738  2823 units, 93.4 mg/kg)
was given after LA access, and the maintenance infusion was 1000
units/hour via a single transseptal sheath with subsequent adjust-
ments based on ACT values. The average ACT was 202 7.5 secondsAddress reprint requests and correspondence: Dr Roger A. Winkle,
Silicon Valley Cardiology, 1950 University Avenue, Suite 160, E. Palo Alto,
CA 94303. E-mail address: rawinkle@aol.com.
1547-5271 B 2014 Heart Rhythm Society. Open access under CC BY-NC-ND license.per procedure, with 116 patients with average ACT o200 seconds
and 16 patients with all ACTs o200 seconds. Complications
occurred in 7 of 372 (1.9%) ablation procedures, including 2
pericardial tamponades (0.54%), 1 groin pseudoaneurysm (0.27%),
and 1 pulmonary embolus, several weeks postablation. There were no
other bleeding events and no strokes/transient ischemic attacks or
systemic thromboemboli.
CONCLUSION Using open-irrigated tip radiofrequency catheters at
50 W and preablation transesophageal echocardiography as well as
infusing maintenance heparin through a single transseptal sheath,
AF ablation can be performed safely despite ACT averaging r210
seconds. While we are not advocating target ACTs this low, our data
suggest that long ACTs may not be absolutely necessary for
preventing thromboembolic events. Lower target ACTs may poten-
tially reduce bleeding complications.
KEYWORDS Atrial ﬁbrillation; Ablation; Anticoagulation
ABBREVIATIONS AAD ¼ antiarrhythmic drug; ACT ¼ activated
clotting time; AF ¼ atrial ﬁbrillation; LA ¼ left atrial; OAC ¼ oral
anticoagulation; PV ¼ pulmonary vein; RF ¼ radiofrequency; TEE ¼
transesophageal echocardiography; TIA ¼ transient ischemic attack
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The consensus guidelines on atrial ﬁbrillation (AF) catheter
ablation recommend an intraprocedural activated clotting
time (ACT) of 300–350 seconds and a higher value of 350–
400 seconds in patients with spontaneous echo contrast noted
on transesophageal or intracardiac echocardiography.1 Gen-
erally accepted recommendations are largely based on
studies performed before the introduction of the open-
irrigated tip radiofrequency (RF) ablation catheter.2–4 Ani-
mal studies show that the open-irrigated tip RF ablationcatheters require a lower tissue interface temperature to
achieve deep tissue heating as compared with closed-tip
catheters, which results in less or no local thrombus
formation.5–7 All intraprocedural anticoagulation strategies
use systemic unfractionated heparin guided by ACTs. Most
centers use target ACTs of 4300–350 seconds. However,
we have previously shown that with the use of open-irrigated
tip ablation catheters, a target ACT of 225 seconds is safe
and reduces hemorrhagic complications without increasing
thromboembolic risks.8 The lower limit of ACTs for
performing an AF ablation with the open-irrigated tip RF
ablation catheter has not previously been established. This
study reports our experience with a subset of patients with an
average ACT r210 seconds with regard to bleeding and
thromboembolic events.http://dx.doi.org/10.1016/j.hrthm.2014.03.013
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Patient population
The participants were 339 patients with symptomatic AF
undergoing 372 left atrial (LA) ablation procedures at
Sequoia Hospital, Redwood City, CA, with initial ablation
from April 2006 to May 2013. Patients were included if their
average ACT during the ablation was r210 seconds. The
data from 106 of 372 (28.5%) ablation procedures were
previously included as part of the ACT o250 group in a
prior article.8 Data collection was prospective and data
analysis was retrospective and approved by the Sequoia
Hospital Institutional Review Board. AF type was catego-
rized as paroxysmal (lasting o1 week), persistent (lasting
41 week and o1 year or requiring pharmacological or
electrical cardioversion in o1 week), and long-standing
persistent (lasting 41 year).1Ablation protocol
Our ablation protocol has been previously published.8–12
Antiarrhythmic drugs (AADs) were discontinued 5 half-lives
and amiodarone at least 3 months before ablation. General
anesthesia was used in all ablation procedures, with all
venous access obtained from the right groin only and arterial
monitoring via either a right femoral or a radial line. A 7F
duodecapolar catheter (Livewire, St Jude Medical,
St Paul, MN) was positioned around the tricuspid annulus
with the distal poles in the coronary sinus. A 9F Ultra ICE
(Boston Scientiﬁc, Natick, MA) intracardiac ultrasound
catheter was used for the transseptal puncture performed
using a 71-cm BRK (St Jude Medical) or NRG (Baylis,
Montreal, QC) needle.11 The NavX (St Jude Medical) or
Carto 3 (Biosense Webster, Diamond Bar, CA) mapping
system was used in all cases. We used 3.5–4.0-mm open-
irrigated tip RF ablation catheters at 50 W and the “perpetual
motion” technique.12 All patients underwent circumferential
pulmonary vein (PV) isolation and linear ablation along LA
roof. Patients with cavotricuspid isthmus–dependent right
atrial ﬂutter or LA isthmus ﬂutter underwent linear ablation
of the appropriate isthmus. Many patients also had low
posterior LA lines and LA complex fractionated atrial
electrograms ablated. Some persistent AF patients underwent
ablation of coronary sinus complex fractionated electro-
grams (at 30–35 W) and superior vena cava isolation. All
PVs were mapped with a circumferential catheter (7F Lasso,
Biosense Webster, or Reﬂexion Spiral, St Jude Medical)
inserted beside the ablation catheter across the single trans-
septal puncture. Speciﬁcally, after the single transseptal
sheath was in place and after heparinization (often later in
the case after the circles have been ablated around the veins
and the roof line is ablated), we placed a dilator and a
guidewire through the transseptal sheath and parked the
guidewire in the left upper PV. We then brieﬂy pulled the
sheath and dilator back into the right atrium, placed our
ablation catheter without a transseptal sheath through the
open transseptal puncture site next to the guidewire, and then
advanced the sheath and dilator back into the LA over theguidewire. The guidewire and dilator are removed, and the
circular mapping catheter was placed through the single
transseptal sheath. We ended up with a single transseptal
sheath containing the circular mapping catheter and a
separate open-irrigated tip RF ablation catheter without a
sheath across the single puncture site. PV isolation was
deﬁned as complete local electrical silence, indicating
entrance block, and after July 2010 we also documented
exit block by pacing from the circumferential catheter.
Activation and entrainment mapping were used to ablate
concomitant atrial ﬂutters and tachycardias. Isoproterenol
was given and non-PV triggers were mapped and ablated.
Anticoagulation
Patients receiving warfarin continued it until 5 days preproce-
dure. Three days preprocedure, they began enoxaparin
(1 mg/kg every 12 hours), with the last dose 24 hours
preprocedure. Patients receiving dabigatran had the drug
discontinued preprocedure by using an algorithm based on
their glomerular ﬁltration rate that was estimated from their
serum creatinine.13 For patients with normal renal function,
dabigatran was held 36 hours preprocedure. Patients receiving
rivaroxaban had the drug discontinued 36 hours preablation.
Patients receiving dabigatran, rivaroxaban, aspirin, or no oral
anticoagulation (OAC) preablation were not bridged with
enoxaparin. Patients with a glomerular ﬁltration rateo15 ml/
min were not considered for dabigatran or rivaroxaban. Patients
underwent preprocedure transesophageal echocardiography
(TEE) under anesthesia and immediately before ablation.
Intraprocedural anticoagulation was achieved with a weight-
based unfractionated heparin bolus of 90–100 units/kg given
when the transseptal sheath entered the LA followed by a 1000
units/h infusion through the transseptal sheath. Additional
heparin administration depended on the ACT, targeted at 225
seconds.8 The initial ACT was noted 10–15 minutes after the
administration of heparin bolus and an ACT was repeated
every 20 minutes if the ACT was out of the target range and
heparin dose adjustments were made and every 30 minutes if
the ACT was in the target range. Heparin was reversed with
intravenous protamine at the end of the ablation, and all sheaths
were removed before leaving the electrophysiology laboratory.
Postablation, all patients received 2 doses of enoxaparin (0.5
mg/kg): the ﬁrst at the end of the procedure and the second 12
hours later. Dabigatran or rivaroxaban was administered the
morning after the procedure. Patients treated with warfarin
postablation resumed the drug the evening of the procedure and
continued enoxaparin (0.5 mg/kg twice daily) until the interna-
tional normalized ratio wasZ2.0.
Complications
Complications were categorized during the ﬁrst 30 days
postablation as death, pericardial tamponade, stroke/transient
ischemic attack (TIA) or systemic thromboembolism, atrioe-
sophageal ﬁstula, PV stenosis450% requiring intervention,
groin complications requiring thrombin injections, surgery,
or transfusion, or other bleeding requiring transfusion.
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For each patient we recorded LA size, age, sex, AF duration,
AF type, number of AADs failed, prior cardioversions, body
mass index, CHADS2 and CHA2DS2-VASc scores and
presence or absence of hypertension, prior stroke/TIA,
diabetes, coronary artery disease, and cardiomyopathy. We
documented OAC preablation and OAC prescribed imme-
diately postablation. We determined the procedure time
(groin access until sheath removal) and the LA time. The
initial heparin bolus dose was evaluated as were all ACT
values.7 NA 1
NA ¼ not available.Data analysis
Continuous data were expressed as mean  SD and
categorical data as counts and percentages. We compared
the clinical characteristics of these patients with average
ACT r210 seconds with those of the patients who under-
went ablation procedures during the same time period with
average ACT 4210 seconds by using the Student t test, χ2
test, and Fisher exact test. All tests were 2-sided, and P o
.05 was considered statistically signiﬁcant. Complication
rates were the number of complications/total number of
ablation procedures. We determined the average ACT during
each ablation as well as the average lowest and the highest
ACT for each procedure and the average number of ACTs
per procedure.Results
Patient population
Table 1 summarizes baseline demographic characteristics of
the 339 patients who underwent a total of 372 ablation
procedures, all with average ACT r210 seconds. This
subset of patients represented 19.4% of all 1745 patients
and 15.9% of all 2334 AF ablation procedures performed at
our institution during the time period of the study. The
average age was 60.9  9.4 years. The CHADS2 score wasTable 1 Clinical characteristics of the patients
No. of patients 339
Left atrial size (cm) 4.27  0.65
Age (y) 60.9  9.4
Sex: female 70 (20.6%)
Duration of AF (y) 6.2  6.3
No. of drugs failed 1.20  1.02
CHADS2 score 0.94  0.98
CHA2DS2-VASc score 1.53  1.35
Hypertension 165 (48.7%)
Diabetes 36 (10.6%)
Body mass index 29.4  5.7
Paroxysmal AF 107 (31.6%)
Persistent AF 200 (59.0%)
Long-standing AF 32 (9.4%)
Prior cardioversion 155 (45.7%)
Coronary artery disease 36 (10.6%)
Dilated cardiomyopathy 25 (7.4%)
Prior stroke/TIA 24 (7.1%)
Values are presented as mean  SD unless speciﬁed.
AF ¼ atrial ﬁbrillation; TIA ¼ transient ischemic attack.0.94  0.98, the CHA2DS2-VASc score was 1.53  1.35,
and 24 (7.1%) of the patients had a prior stroke/TIA. Table 2
gives the number of patients stratiﬁed by CHADS2 and
CHA2DS2-VASc scores. The ablation was an initial ablation
in 339 (91.1%) of the procedures and a redo ablation in 33
(8.9%).
We compared the patient characteristics of the 339
patients with average ACT r210 seconds with those of
the 1406 patients with average ACT4210 seconds (average
ACT 241  39 seconds) who underwent ablation proce-
dures. When compared with patients with average ACT
r210 seconds, patients with average ACT 4210 seconds
had no difference in LA size (4.28  0.68 cm; P ¼ .90),
duration of AF preablation (6.4  7.4 years; P ¼ .62),
number of patients with paroxysmal AF (449 (31.9%); P ¼
.948), number of AADs failed (1.29  1.03; P ¼ .12),
number of patients with prior cardioversion (662 (47.1%);
P¼ .11), or the incidence of hypertension (759 (54.0%); P¼
.077), prior stroke/TIA (122 (8.7%); P ¼ .65), or diabetes
(157 (11.2%); P ¼ .70). Patients with ACTs4210 seconds
were more likely to be women (453 (32.2%); P o .005),
were older (64.3  9.8 years; Po .001), and as a result had
higher CHADS2 (1.12  1.08; P o .003) and CHA2DS2-
VASc (2.00  1.48; P o .001) scores.
Pre- and postprocedural anticoagulation
The preablation anticoagulant was warfarin in 132 (35.5%),
dabigatran in 65 (17.5%), and rivaroxaban in 46 (12.1%)
ablation procedures. There were 129 low-risk patients of
whom 104 (28.0%) were receiving aspirin and 25 (6.7%)
were receiving no OAC preablation. After the ablation
procedures, 178 (47.8%) were receiving warfarin, 115
(30.9%) were receiving dabigatran, and 78 (21.0%) were
receiving rivaroxaban. One low-risk patient with pericardial
tamponade was treated initially with no OAC and subse-
quently with aspirin postablation.
Intraprocedural anticoagulation
The heparin bolus (8738  2823 units, 93.4 mg/kg) was
given after LA access, and the maintenance infusion through
the transseptal sheath was started at 1000 units/h with
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2.88  0.91 ACT measurements per ablation. By deﬁnition,
for inclusion in the study, all patients had an average ACT of
r210 seconds. For all the 372 ablation procedures, the
average ACT was 202  7.5 seconds per procedure, with
116 patients with average ACT o200 seconds and 16
patients with all ACTs o200 seconds. The average initial
ACT was 198  15 seconds per procedure, the average
lowest ACT was 189  37 seconds per procedure, and the
average highest ACT was 216  18 seconds per procedure.
Procedure time and LA time were 119  26 and 82  24
minutes, respectively.
Complications
Complications occurred in 7 of 372 (1.9%) ablation proce-
dures, including 2 pericardial tamponades (0.54%) both
treated with pericardiocentesis, 1 groin pseudoaneurysm
(0.27%) requiring surgical intervention, and 1 pulmonary
embolus, several weeks postablation. Two patients had a
persistent cough, and 1 had pneumonia. All complications
resolved without sequelae. There were no other bleeding
events and no strokes/TIAs or systemic thromboemboli. No
patients required blood transfusion. There were no deaths,
atrioesophageal ﬁstulae, or PV stenoses.
Discussion
Lower target ACTs can reduce bleeding complications
during AF ablation.8 In this study, we report our experience
with 372 ablation procedures in 339 patients with sympto-
matic AF whose average intraprocedural ACT was r210
seconds. We evaluated all ablation procedures after April
2006 when we began using the open-irrigated tip RF ablation
catheters at a power setting of 50 W12 and reduced our target
intraprocedural ACT to 225 seconds.8 The major ﬁndings of
this study are as follows: (1) using preablation TEE and a
single transseptal puncture as well as infusing maintenance
heparin through the transseptal sheath, these low ACT values
were not associated with clinically apparent cerebral or
systemic thromboemboli and (2) these observations raise
questions about the necessity of keeping target ACT4300–
350 seconds for AF ablation when using open-irrigated tip
RF ablation catheters.
AF ablation procedures have a signiﬁcant rate of compli-
cations. In a self-reporting registry of 20,825 ablation
procedures,14 the rate of pericardial tamponade was 1.31%,
with a stroke rate of 0.23% and a TIA rate of 0.71%. There
was 1 death for every 833 AF ablation procedures. Several
non–self-reporting evaluations of AF ablation procedures
found a substantially higher rate of serious complications.15–17
In these studies, pericardial tamponade rates ranged from
1.5% to 3.1%, stroke/TIA rates from 0.6 to 1.0%, and
procedure-related deaths from 1 for 416 to 1 for 217 ablation
procedures. The most sobering ﬁnding among all these
studies is that for all 93,801 AF ablation procedures
performed in the United States from 2000 to 2010, 81%
were performed by operators who perform o25 ablationprocedures per year and there was 1 in-hospital death for
every 217 patients. Many of these complications were
hemorrhagic, and any change in technique that might lower
the overall complication rate should be welcomed as long as
it does not increase the rate of thromboembolic events.
Because of concerns about cerebral or systemic throm-
boembolism, AF ablation guidelines recommend quite long
ACTs.1 These recommendations are based, in part, on early
echocardiographic observations of LA thrombi associated
with the transseptal sheath,2 particularly when using 2 trans-
septal sheaths for LA access. LA thrombus was visualized in
11.2% of the patients when the ACT was 250–300 seconds
and in 2.8% with ACTs between 300 and 410 seconds. In
that study,2 transseptal sheaths were continually ﬂushed with
a heparinized solution but the heparin concentration was not
speciﬁed. Maleki et al3 also evaluated thrombus formation
on the transseptal sheath using a 2-sheath technique. The
target ACT was 250–300 seconds, and both sheaths were
perfused continually with low heparin concentration infu-
sate. Thrombus was observed in 9% of the patients with
sheaths preﬂushed with a lower heparin concentration and in
only 1% of the patients with sheaths preﬂushed with a higher
heparin concentration. Our use of only a single transseptal
sheath and infusing 1000 units/h maintenance heparin
through this sheath minimizes the risk of sheath-associated
thrombus and allows us to safely maintain a lower ACT
value.
In addition to sheath-associated thrombus, the other
justiﬁcation for long ACTs is to prevent the occurrence of
char on the ablation catheter. Virtually all clinical studies
examining char formation did not use the current open-
irrigated tip RF ablation catheters.2–4
Wazni et al4 examined thromboembolic events and char
formation in patients undergoing AF ablation using an
ultrasound balloon ablation system. Char formation was
detected in 35.6% of the patients with ACTs between 250
and 300 seconds and in only 1.9% of the patients with
ACTs between 350 and 400 seconds. An embolic event
occurred in 3.6% of the patients in the lowest ACT group
and in 0.5% of the patients in the highest ACT group.
Studies with this ultrasound balloon ablation system may
have no relevance to char formation with the open-irrigated
tip RF ablation catheters. Animal data evaluating open-
irrigated tip RF ablation catheters also suggest that studies
that evaluated char formation using closed-tip RF ablation
catheters may have no relevance to the use of the open-
irrigated tip catheter. Ablation requires tissue heating to
4501C to form scar via coagulation necrosis. These animal
studies show that the closed-tip RF ablation catheters
require heating of the catheter-tissue interface to a temper-
ature that is only 3–71C lower than that of the tissue
temperature.5 The open-irrigated tip RF ablation catheter
requires only a few degrees increase in tip temperature to
create a 20–301C increase in tissue temperature.6 This lack
of major local tissue heating at the catheter-tissue interface
makes it almost impossible to form char, regardless of
the ACT value. In animal studies, the open-irrigated tip
967Winkle et al Low ACT and AF Ablationtemperature never reached 801C, the catheter-tissue inter-
face temperature required to form a thrombus.7 These
animal studies are consistent with our prior clinical study.8
In 1122 AF ablation procedures, we found that there was no
increase in strokes/TIAs or systemic thromboemboli asso-
ciated with the lower ACTs. In addition, our vascular and
hemorrhagic complications increased linearly as a function
of ACT. As the ACT increased from o250 to 4350
seconds, the complication rate increased from 1.62% to
5.55%. In our prior study, multivariate analysis showed that
only the use of the open-irrigated tip RF ablation catheter
compared with the non-irrigated closed tip RF ablation
catheter RF ablating was predictive of fewer complications.
Although our patients with ACTs 4210 seconds had
most of the clinical characteristics similar to those of the
patients with ACTs r210 seconds, they were different in
2 aspects: they were older and more were women. Both these
differences could largely explain the differences in CHADS2
and CHA2DS2-VASc scores. These differences can be
explained by the pharmacokinetic proﬁle of heparin. We
have previously noted that when giving all patients a similar
loading dose of heparin (in mg/kg), there is a preponderance
of women in patients with higher ACT values.8 Campbell
et al18 reported sex differences during heparin administration
in patients treated for leg deep venous thrombosis. In that
study, both men and women were given a standard heparin
bolus and infusion. Women had both higher heparin levels
and higher activated partial thromboplastin time compared
with men. Older women had higher heparin levels for any
dose of heparin. At our center, the average age of women
undergoing ablation is 4 years greater than that of men
(66.4 9.6 years vs 62.6 9.6 years). This pharmacokinetic
property of heparin most likely accounts for both the
increased age and the greater proportion of women in the
ACT 4210 group.
We do not advocate keeping the target ACT as low as the
ACTs observed in the present group of patients. We still feel
that a target level of 225–250 seconds is reasonable. However,
the lack of complications in our low ACT cohort strongly
suggest that extremely high ACTs (4300 seconds) are not
necessary to prevent thromboembolic events during an AF
ablation procedure. These longer ACTs may even contribute
to higher bleeding and vascular complication rates.8
There are several issues to emphasize regarding our
extremely safe experience with low ACTs. We use only a
single groin for all venous access. We perform only a single
transseptal puncture and we infuse 1000 units/h maintenance
heparin directly through the transseptal sheath, frequently
delivering high-dose heparin into the LA. The time spent
ablating within the LA is relatively short, in part reﬂecting
experienced operators, but mostly reﬂecting the use of 50 W,
which requires substantially less ablation time at any
particular location. We have previously published our
experience using higher ablation power delivered for shorter
times at each location and have demonstrated fewer compli-
cations, shorter procedural times, and better long-term
outcomes.12Study limitations
This was a nonrandomized retrospective evaluation. Our
ﬁndings cannot be extrapolated to the use of closed-tip RF
ablation catheters or cryoballoon ablation catheters. It cannot
be applied to the use of double transseptal punctures or
infusing maintenance heparin through a non-transseptal
sheath. Our ﬁndings may not apply to the use of power less
than 50 W, since procedures using lower power are likely to
take considerably longer than our average of 119 minutes.
Because magnetic resonance imaging was not performed
pre- and postablation, we cannot make any comments about
the occurrence of subclinical cerebral thromboembolic
lesions. All of these patients were enrolled at a single high-
volume center with expertise in performing AF ablation.
Although it is not known if CHADS2 and CHA2DS2-VASc
scores predict procedural complications, our patients had
lower scores than did patients who underwent ablation
procedures at our center with average ACT 4210 seconds,
which may have contributed to our lack of thromboembolic
events.
Conclusion
Using preablation TEE and open-irrigated tip RF ablation at
50 W as well as infusing maintenance heparin through a
single transseptal sheath, AF ablation can be performed safely
despite ACTs averaging r210 seconds. While we do not
advocate such a low target for ACTs, our data suggest that
long ACTs may not be absolutely necessary for the preven-
tion of thromboembolic events and, in fact, somewhat lower
target ACTs may potentially reduce bleeding complications.
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